ARTICLE | Clinical News

MethylGene starts MG98 Phase II

October 6, 2004 7:00 AM UTC

MethylGene (TSE:MYG) began a two-step Phase II trial of its MG98 plus interferon alpha in patients with metastatic renal cell cancer. The first portion of the trial will evaluate safety, pharmacokinetics and optimal dosing of the combination therapy in 30-50 chemotherapy-naive patients. The second portion will evaluate progression-free survival in about 200 patients in Europe and North America. The primary endpoint of the trial is median progression-free survival. Secondary endpoints include tolerability, one-year survival, tumor response and overall survival. ...